VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
S.F. Holding Co., Ltd. vs AstraZeneca PLC
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
S.F. Holding Co., Ltd.
002352 · Shenzhen Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into S.F. Holding Co., Ltd.'s moat claims, evidence, and risks.
View 002352 analysisAstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.
View AZN analysisComparison highlights
- Moat score gap: S.F. Holding Co., Ltd. leads (75 / 100 vs 71 / 100 for AstraZeneca PLC).
- Segment focus: S.F. Holding Co., Ltd. has 7 segments (43% in Time-definite Express); AstraZeneca PLC has 6 segments (41% in Oncology).
- Primary market structure: Quasi-Monopoly vs Oligopoly. Pricing power: Strong vs Strong.
- Moat breadth: S.F. Holding Co., Ltd. has 9 moat types across 3 domains; AstraZeneca PLC has 4 across 3.
Primary market context
S.F. Holding Co., Ltd.
Time-definite Express
Premium time-definite parcel express delivery services
China
B2B, B2C
Integrated parcel pickup, sorting, line-haul, and last-mile delivery
43%
AstraZeneca PLC
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Global
Hospitals, oncology clinics, payers
Innovator biopharmaceutical company
41%
Side-by-side metrics
Moat coverage
Shared moat types
S.F. Holding Co., Ltd. strengths
AstraZeneca PLC strengths
Segment mix
S.F. Holding Co., Ltd. segments
Full profile >Time-definite Express
Quasi-Monopoly
Economy Express
Oligopoly
LTL Freight
Competitive
Cold Chain & Pharmaceutical
Competitive
Intra-city On-demand
Oligopoly
Supply Chain & International
Competitive
Other (Non-logistics & Undistributed Units)
Competitive
AstraZeneca PLC segments
Full profile >Oncology
Oligopoly
Cardiovascular, Renal and Metabolism (CVRM)
Competitive
Respiratory & Immunology (R&I)
Oligopoly
Vaccines & Immune Therapies (V&I)
Oligopoly
Rare Disease
Oligopoly
Other Medicines
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.